Nivolumab after sorafenib failure in liver recipients with hepatocellular carcinoma recurrence

被引：0
|
作者：
Kwon, J. [1 ]
Park, S. [1 ]
Yun, S. O. [1 ]
Yang, J. [1 ]
Lim, M. [1 ]
Rhu, J. [1 ]
Choi, G. -S. [1 ]
Kim, J. M. [1 ]
Joh, J. -W. [1 ]
机构：
[1] Samsung Med Ctr, Surg, Seoul, South Korea
来源：
TRANSPLANTATION | 2023年 / 107卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
eP-442
引用
收藏
页码：265 / 265
页数：1
相关论文
共 50 条
  • [1] Nivolumab After Sorafenib Failure in Liver Recipients with HCC Recurrence.
    Kwon, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 824 - 824
  • [2] Sorafenib for Hepatocellular Carcinoma Recurrence After Liver Transplant
    Mancuso, Andrea
    TRANSPLANTATION, 2020, 104 (08) : E243 - E243
  • [3] Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation
    Weinmann, Arndt
    Niederle, Ina Maria
    Koch, Sandra
    Hoppe-Lotichius, Maria
    Heise, Michael
    Dueber, Christoph
    Schuchmann, Marcus
    Otto, Gerd
    Galle, Peter Robert
    Woerns, Marcus-Alexander
    DIGESTIVE AND LIVER DISEASE, 2012, 44 (05) : 432 - 437
  • [4] Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
    Kuo, Yuan-Hung
    Yen, Yi-Hao
    Chen, Yen-Yang
    Kee, Kwong-Ming
    Hung, Chao-Hung
    Lu, Sheng-Nan
    Hu, Tsung-Hui
    Chen, Chien-Hung
    Wang, Jing-Houng
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [5] Sorafenib for Hepatocellular Carcinoma Recurrence After Liver Transplant Reply
    Invernizzi, Federica
    Iavarone, Massimo
    TRANSPLANTATION, 2020, 104 (08) : E244 - E244
  • [6] EVEROLIMUS AND SORAFENIB FOR RECURRENCE OF HEPATOCELLULAR CARCINOMA AFTER LIVER TRANSPLANTATION
    De Simone, Paolo
    Pezzati, Daniele
    Lai, Quirino
    Ghinolfi, Davide
    Coletti, Laura
    Precisi, Arianna
    Leonardi, Giulia
    Carrai, Paola
    Filipponi, Franco
    TRANSPLANT INTERNATIONAL, 2013, 26 : 293 - 293
  • [7] Sorafenib Prophylaxis Is Effective in Preventing Hepatocellular Carcinoma Recurrence in Liver Transplant Recipients
    Saab, Sammy
    McTigue, Mike
    Finn, Richard
    Busuttil, Ronald W.
    LIVER TRANSPLANTATION, 2010, 16 (06) : S192 - S192
  • [8] Lenvatinib versus sorafenib for recurrence of hepatocellular carcinoma after liver transplantation
    Perera, S.
    Magyar, C. T. J.
    Rajendran, L.
    Li, Z.
    Almugbel, F. A.
    Feng, S.
    Choi, W. J.
    Aceituno, L.
    Selzner, N.
    Jaeckel, E.
    Falla-Rad, N.
    Knox, J. J.
    Chen, E. X.
    O'Kane, G. M.
    Sapisochin, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S82 - S83
  • [9] Sorafenib Reduced Recurrence of Large Hepatocellular Carcinoma after Liver Transplantation
    Asham, Emad
    Boktour, Maha
    Mcfaden, Robert
    Monsour, Howard
    Gaber, Osama
    Ghobrial, R. Mark
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 88 - 88
  • [10] Sorafenib in Liver Transplant (LT) Recipients at High Risk of Hepatocellular Carcinoma (HCC) Recurrence
    Yan, W.
    Agrawal, N.
    Gadwale, G.
    Laurin, J.
    Satoskar, R.
    Manzanares, K.
    He, R.
    Johnson, L.
    Fishbein, T.
    Shetty, K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 113 - 113
12345